S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
NASDAQ:YS

YS Biopharma (YS) Stock Price, News & Analysis

$0.94
+0.08 (+9.35%)
(As of 04/17/2024 ET)
Today's Range
$0.80
$0.96
50-Day Range
$0.38
$0.94
52-Week Range
$0.35
$2.37
Volume
413,726 shs
Average Volume
199,102 shs
Market Capitalization
$87.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25

YS Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
460.9% Upside
$5.25 Price Target
Short Interest
Healthy
0.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of YS Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.49) to ($0.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

Medical Sector

332nd out of 913 stocks

Pharmaceutical Preparations Industry

132nd out of 398 stocks

YS stock logo

About YS Biopharma Stock (NASDAQ:YS)

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

YS Stock Price History

YS Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
YS Biopharma Announces Appointment of New Directors
YS Biopharma Announces Appointment of New Directors
See More Headlines
Receive YS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for YS Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/22/2024
Today
4/18/2024
Next Earnings (Confirmed)
4/19/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
754
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.25
High Stock Price Target
$5.25
Low Stock Price Target
$5.25
Potential Upside/Downside
+460.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$100 million
Book Value
$1.14 per share

Miscellaneous

Free Float
N/A
Market Cap
$87.10 million
Optionable
Not Optionable
Beta
0.53
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Gang Li (Age 42)
    Head of Marketing & Sales
  • Dr. Yuan Liu Ph.D. (Age 37)
    Head of Vaccine Research
  • Dr. Hui Shao Ph.D. (Age 56)
    President, CEO & Executive Director
  • Ms. Chunyuan Wu CPA (Age 46)
    Chief Financial Officer & Director
  • Dr. Zenaida Reynoso Mojares (Age 65)
    Chief Medical Officer

YS Stock Analysis - Frequently Asked Questions

Should I buy or sell YS Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for YS Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" YS shares.
View YS analyst ratings
or view top-rated stocks.

What is YS Biopharma's stock price target for 2024?

1 brokerages have issued 12 month price targets for YS Biopharma's stock. Their YS share price targets range from $5.25 to $5.25. On average, they expect the company's stock price to reach $5.25 in the next year. This suggests a possible upside of 460.9% from the stock's current price.
View analysts price targets for YS
or view top-rated stocks among Wall Street analysts.

How have YS shares performed in 2024?

YS Biopharma's stock was trading at $0.5110 at the beginning of the year. Since then, YS stock has increased by 83.2% and is now trading at $0.9360.
View the best growth stocks for 2024 here
.

Are investors shorting YS Biopharma?

YS Biopharma saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 96,900 shares, a decrease of 17.0% from the March 15th total of 116,800 shares. Based on an average trading volume of 211,800 shares, the short-interest ratio is presently 0.5 days. Approximately 0.5% of the company's shares are sold short.
View YS Biopharma's Short Interest
.

When is YS Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 19th 2024.
View our YS earnings forecast
.

How were YS Biopharma's earnings last quarter?

YS Biopharma Co., Ltd. (NASDAQ:YS) issued its earnings results on Monday, January, 22nd. The company reported ($0.16) EPS for the quarter. The business earned $13.64 million during the quarter.

How do I buy shares of YS Biopharma?

Shares of YS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners